Q-omics provides the consensus-scored CLUHP11 profile across patient tissues and cancer cell-line models. CLUHP11 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CLUHP11 is differentially expressed in 1, with the highest sampling consensus in ESCA. Additionally, CLUHP11 RNA expression shows 4,429 significant gene co-expression associations, with the highest sampling consensus in BRCA. Together, these results highlight SKCM, ESCA, and BRCA as cancer lineages where CLUHP11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLUHP11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLUHP11 survival associations across molecular data types. CLUHP11 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLUHP11 RNA expression–survival associations across cancer types. High CLUHP11 expression shows unfavorable associations in SKCM, LUSC, THYM and KIRC, but favorable associations in LAML and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for CLUHP11 RNA expression.
This table summarizes CLUHP11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for CLUHP11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLUHP11 shows lower tumor expression in ESCA. The ESCA box plot shows higher CLUHP11 RNA expression in normal versus tumor tissue (log2 FC = −0.075, t-test p = .012).
This table shows molecular features associated with CLUHP11 in patient tissues and cancer cell lines. In patient samples, CLUHP11 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
